Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease

Neurology. 1986 Sep;36(9):1200-5. doi: 10.1212/wnl.36.9.1200.

Abstract

Twenty patients with type I Charcot-Marie-Tooth disease received dietary supplementation with the essential fatty acids (EFA), linoleic and gamma-linolenic acids, and vitamin E. A 3-month blinded trial of placebo (paraffin oil and vitamin E, 81.6 IU/d) was followed by 1 year of 3 grams daily of EFA and vitamin E. Serum fatty acid values doubled, but total esterified fatty acid proportions did not change. Arachidonic acid proportions correlated with the amount of prostaglandin-mediated lymphocyte suppression measured at the same times. Improvement demonstrated at the end of the placebo period by neuropsychological tests and neurologic examination was maintained during the 1 year of EFA supplementation. This effect may reflect a membrane stabilization benefit of vitamin E.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Arachidonic Acids / blood
  • Arachidonic Acids / pharmacology
  • Charcot-Marie-Tooth Disease / blood*
  • Charcot-Marie-Tooth Disease / drug therapy
  • Charcot-Marie-Tooth Disease / psychology
  • Fatty Acids / administration & dosage
  • Fatty Acids / blood*
  • Female
  • Humans
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Muscular Atrophy / blood*
  • Neuropsychological Tests
  • Vitamin E

Substances

  • Arachidonic Acids
  • Fatty Acids
  • Vitamin E